C. Peters, S. Sokolov, S. Rajamani
Jun 1, 2013
Citations
4
Influential Citations
25
Citations
Journal
British Journal of Pharmacology
Abstract
Ranolazine is an antianginal drug currently approved for treatment of angina pectoris in the United States. Recent studies have focused on its effects on neuronal channels and its possible therapeutic uses in the nervous system. We characterized how ranolazine affects the brain sodium channel, NaV1.2, and how its actions are modulated by low pH. In this way, we further explore ranolazine's potential as an anticonvulsant and its efficacy in conditions like those during an ischaemic stroke.